The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Mega Mergers
Stock Buybacks
Stock Buybacks
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement
COLL Buyback image

Collegium Pharmaceutical, Inc. Buyback

OLI recorded this information on 11/9/2023

Company: Collegium Pharmaceutical, Inc.
Buyback: COLL buyback
$Amount Authorized: $25,000,000
Buyback Details: Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company's common stock. Collegium will execute the ASR as part of the $100 million share repurchase program authorized by its Board of Directors in January 2023. Upon completion of this ASR, Collegium will have $25 million remaining under the program.

Collegium Pharmaceutical is a pharmaceutical company. Co.'s portfolio includes: Xtampza ER, Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. Xtampza ER was approved by the U.S. Food and Drug Administration for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.

COLL SEC Filing Email Alerts Service

Open the COLL Page at The Online Investor »

COLL — Key Stats (updated 20 hours, 19 minutes ago)
Company Name:  Collegium Pharmaceutical Inc
Stock buyback:  COLL buyback
Website:  www.collegiumpharma.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding COLL:  50
Total Market Value Held by ETFs:  $262.18M
Total Market Capitalization:  $1.18B
% of Market Cap. Held by ETFs:  22.22%
 

Open the COLL Page at The Online Investor (in a new window) »
May 3, 2024  •  7:21 AM Eastern
COLL — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree COLL Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Buy (3.17 out of 4)
37th percentile
(ranked lower than approx. 63% of all stocks covered)

Analysts' Target Price:
COLL Stock Forecast

 Based on Zacks ABR data;
powered by Xignite

COLL Buyback | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.